SARS-CoV-2 Clinical Management, Respiratory Support and Long-COVID Sequelae
This community focuses on the clinical management of SARS-CoV-2 infection, with a heavy emphasis on respiratory care, oxygen therapy, and the characterization of long-term sequelae in patients.
The research is dominated by clinical studies of acute respiratory distress, respiratory failure, and the application of high-flow nasal oxygen therapy and nasal cannulas in severe cases. A significant portion of the work examines metabolic markers, specifically blood urea and urea nitrogen, alongside albumin ratios, to assess patient status. The literature also extensively covers vaccination strategies against SARS-CoV-2, the development of vaccines, and the immune response to the virus. Recent attention has shifted toward defining and managing long-COVID, including symptoms in non-hospitalized adults and the underlying immune dysregulation. The community also engages with magnetic resonance imaging for diagnostic purposes and the pathophysiology of severe acute respiratory syndrome.
The largest share of the community's output is found in oxygen research, accounting for 0.2% of all oxygen research, with 1,000 papers in this group. Nitrogen research follows with 543 papers, representing 0.1% of that element's total research. Gadolinium research contributes 268 papers, which is 0.4% of all gadolinium research.
The community comprises 10,235 papers, publishing most frequently in Dermatologic Therapy, Signal Transduction and Targeted Therapy, and bioRxiv (Cold Spring Harbor Laboratory).
Recent work continues to focus on SARS-CoV-2 variants, including loss-of-function mutations in Omicron, and the management of acute respiratory distress syndrome in critically ill patients. There is also emerging research on the vascular complications of long-COVID and the use of computational tools for designing protein nanoparticle immunogens.